NNZ-2591 is under clinical development by Neuren Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NNZ-2591’s likelihood of approval (LoA) and phase transition for Prader-Willi Syndrome (PWS) took place on 01 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NNZ-2591 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NNZ-2591 overview

NNZ-2591 is under development for the treatment of Phelan-McDermid syndrome, Angelman Syndrome, Pitt Hopkins syndrome (genetic disorders), Fragile X syndrome, stroke, peripheral neuropathy, memory impairment, cognitive impairment, traumatic brain injury, multiple sclerosis, Prader-Willi syndrome and Parkinson’s disease. The drug candidate is administered orally. It is a synthetic analog of the neurotrophic peptide cyclic glycine proline, a naturally occurring neuropeptide. It belongs to the diketopiperazine family.

Neuren Pharmaceuticals overview

Neuren Pharmaceuticals (Neuren Pharma) is a biopharmaceutical company that develops drugs for brain injury, neurodevelopmental and neurodegenerative disorders. The company pipeline products includes trofinetide, NNZ-2591 and NNZ-2566. Its trofinetide has a pharmacokinetic profile, which is suitable for intravenous infusion and oral delivery. Neuren Pharma undertakes clincal trials for several drugs. The company’s trofinetide is a clinical stage drug candidate it provides molecule which is derived from IGF-1 and occurs naturally in the brain. Its drugs are also used in neurodevelopmental disorders such as angelman syndrome and idiopathic autism, or neurodegenerative disorders such as Parkinson’s disease and multiple sclerosis. Neuren Pharma is headquartered in Camberwell, Victoria, Australia.

Quick View NNZ-2591 LOA Data

Report Segments
  • Innovator
Drug Name
  • NNZ-2591
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genetic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.